Skip to main content

Clinical Trials Using Decitabine and Cedazuridine

Review the clinical trials studying decitabine and cedazuridine on this list and use the filters to refine the results by age and location. Some clinical trials are held at NCI-Designated Cancer Centers and may be supported by other organizations.

You can find more information about the types and phases of clinical trials and what to expect or use our Steps to Find a Clinical Trial.

Trials 1-25 of 30

Testing the Addition of an IDH2 Inhibitor, Enasidenib, to Usual Treatment (Cedazuridine-Decitabine) for Higher-Risk Myelodysplastic Syndrome (MDS) with IDH2 Mutation (A MyeloMATCH Treatment Trial)
Status: Active
Location: 140 locations
Comparing New Treatments for People with Newly Diagnosed Acute Myeloid Leukemia That Has an IDH2 Gene Change (A MyeloMATCH Treatment Trial)
Status: Active
Location: 125 locations
A Randomized Study of ASTX727 with or without Iadademstat in Advanced Myeloproliferative Neoplasms (MPNs)
Status: Active
Location: 31 locations
Testing the Anti-cancer Drug, Cirtuvivint, and its Combination with ASTX727 to Improve Outcomes in Patients with Acute Myeloid Leukemia and Myelodysplastic Syndromes
Status: Active
Location: 21 locations
Testing the Addition of an Anti-cancer Drug, ASTX727 (Cedazuridine, Decitabine), to Chemotherapy (Paclitaxel) and Immunotherapy (Pembrolizumab) for Metastatic Triple-Negative Breast Cancer
Status: Active
Location: 9 locations
Testing the Combination of Nivolumab and ASTX727 for Relapsed or Refractory B-Cell Lymphoma
Status: Active
Location: 8 locations
ASTX727 for the Treatment of Malignant Nerve Sheath Tumors with PRC2 Mutation Loss
Status: Active
Location: 7 locations
Decitabine and Cedazuridine for Early Treatment of High-Risk Clonal Cytopenia of Undetermined Significance
Status: Active
Location: 5 locations
ASTX727 for the Treatment of Advanced, Unresectable, or Metastatic Solid Tumors
Status: Active
Location: 2 locations
A Study to Find the Highest Dose of Cedazuridine and Decitabine Combination with Filgrastim as a Treatment Option after Hematopoietic Stem Cell Transplant in Children with High-Risk Acute Myeloid Leukemia
Status: Active
Location: 2 locations
Avapritinib in Combination with Decitabine for the Treatment of Patients with Systemic Mastocytosis with an Associated Hematologic Neoplasm
Status: Active
Location: 2 locations
ASTX727 and Dasatinib for the Treatment of Newly Diagnosed Philadelphia Chromosome or BCR-ABL Positive Chronic Myeloid Leukemia in Chronic Phase
Status: Active
Location: M D Anderson Cancer Center, Houston, Texas
Olutasidenib in Combination with Hypomethylation Therapy for the Treatment of IDH1-Mutated Higher-Risk Myelodysplastic Syndromes, Chronic Myelomonocytic Leukemia, and Myeloproliferative Neoplasms
Status: Active
Location: M D Anderson Cancer Center, Houston, Texas
Pacritinib With Standard of Care Azacitidine or Decitabine as a Bridge to Allogeneic Hematopoietic Stem Cell Transplant for Patients with Accelerated and Blast Phase Myeloproliferative Neoplasms
Status: Active
Location: Fred Hutch/University of Washington/Seattle Children's Cancer Consortium, Seattle, Washington
SNDX-5613 with Decitabine/Cedazuridine, and Venetoclax for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia, SAVE Trial
Status: Active
Location: M D Anderson Cancer Center, Houston, Texas
Decitabine/Cedazuridine and Venetoclax in Combination with Ivosidenib or Enasidenib for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia
Status: Active
Location: M D Anderson Cancer Center, Houston, Texas
Decitabine and Cedazuridine for the Improvement of Outcomes in Myelodysplastic Syndrome Patients with Measurable Residual Disease after Donor Stem Cell Transplantation
Status: Active
Location: Siteman Cancer Center at Washington University, Saint Louis, Missouri
ASTX727, Venetoclax, and Gilteritinib for the Treatment of Newly Diagnosed, Relapsed or Refractory FLT3-Mutated Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome
Status: Active
Location: M D Anderson Cancer Center, Houston, Texas
Decitabine Alone or in Combination with Venetoclax, Gilteritinib, Enasidenib, or Ivosidenib as Maintenance Therapy for the Treatment of Acute Myeloid Leukemia in Remission
Status: Active
Location: M D Anderson Cancer Center, Houston, Texas
Study to Evaluate the Pharmacokinetics and Safety of Oral Decitabine and Cedazuridine in Cancer Patients With Hepatic Impairment
Status: Active
Location: M D Anderson Cancer Center, Houston, Texas
Study to Evaluate the Pharmacokinetics and Safety of Oral Decitabine and Cedazuridine in Cancer Patients With Renal Impairment
Status: Active
Location: M D Anderson Cancer Center, Houston, Texas
Olaparib and ASTX727 for the Treatment of Patients with BRCA 1/2 and HRD Mutated Advanced Tumors
Status: Active
Location: University of California San Francisco, San Francisco, California
Venetoclax in Combination with ASTX727 for the Treatment of Pediatric Patients with Relapsed or Refractory Acute Myeloid Leukemia
Status: Active
Location: M D Anderson Cancer Center, Houston, Texas
A Study for Participants Who Participated in Prior Clinical Studies of ASTX727 (Standard Dose)
Status: Enrolling by Invitation
Location: 2 locations
ASTX727 (Decitabine/Cedazuridine) and Retifanlimab-dlwr for the Treatment of Advanced/Unresectable Merkel Cell Carcinoma
Status: Approved
Location: University of Wisconsin Carbone Cancer Center - University Hospital, Madison, Wisconsin